The FDA decision on MediWound Ltd.’s (MDWD) NexoBrid, proposed for removal of eschar with deeppartial and full-thickness thermal burns, is due on January 1, 2023.
NexoBrid, which is a Bromelain-based topical biological product containing a sterile mixture of proteolytic enzyme, effectively and selectively removes burn eschar within 4 hours of a single application without harming surrounding viable tissue.
The product is already approved in 41 countries, including the European Union.
Vericel holds an exclusive license for North American commercial rights to NexoBrid.
MDWD closed Friday’s trading at $11.50, up 5.02%.